Key Takeaways Camzyos met primary and key secondary endpoints in SCOUT-HCM, showing reduced LVOT obstruction in adolescentsPositive data support Camzyos as a potential first CMI for adolescent oHCM, expanding beyond adult approval.BMY's portfolio also relies on Eliquis, while the milvexian Librexia ACS study was discontinued Bristol Myers’ (BMY) cardiovascular portfolio currently comprises blockbuster drugs Eliquis and Camzyos.The company recently reported positive top-line results from the late-stage SCOUT ...